All Helicobacters are urease-positive, able to convert aminoacids and urea into ammonia to neutralize stomach acid, andhighly mobile – characteristics that help them invade the mucosallayer to evade the body’s immune response. Helicobacter pylori(H. pylori) is linked to peptic ulcer disease, chronic gastritis,gastric mucosa-associated lymphoid tissue lymphoma, andearly gastric cancer. The infection rate of H. pylori is over 80% indeveloping countries and 20–50% in industrialized nations, withover 4.4 billion people testing positive for the bacteria in 2015.1,2
There is an increasing number of studies that shed light on the importance of our gut microbiota. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. With new data emerging about their proposed benefits in maintaining intestinal health, probiotics continue to gain popularity amongst consumers.
Last August, the article 'Role of General Practitioners in Early Detection of Inflammatory Bowel Disease' highlighted proper screening and early specialist referral by the general practitioner (GP) as vital components in reducing the burden of inflammatory bowel disease (IBD). This year, the focus is on the role of GPs in co-managing a patient with IBD at the follow-up phase.
Nonalcoholic fatty liver disease (NAFLD), including simple steatosis and nonalcoholic steatohepatitis (NASH), is widely considered as the liver manifestation of the metabolic syndrome. It is a major cause of liver disease worldwide and its prevalence is expected to rise in tandem with the rising prevalence of obesity and diabetes mellitus. Recently, MIMS Doctor spoke to Associate Professor Dr Wah Kheong Chan, a Consultant Physician and Gastroenterologist at the University of Malaya Medical Centre and University of Malaya Specialist Centre, to provide an update on NAFLD, with a particular emphasis on the use of silymarin for the treatment of NASH. Here are the highlights from the interview.
Constipation is a common disorder which adversely affects the wellbeing and quality of life of patients.1 Recently, MIMS Doctor spoke to Associate Prof Dr Raja Affendi Raja Ali on the landscape of constipation in Malaysia, emphasizing on effective and early management of the condition.
Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.
Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.